Aberrant retinoblastoma (RB)-E2F transcriptional regulation defines molecular phenotypes of osteosarcoma

Milcah C. Scott, Aaron L. Sarver, Hirotaka Tomiyasu, Ingrid Cornax, Jamie Van Etten, Jyotika Varshney, M. Gerard O'Sullivan, Subbaya Subramanian, Jaime F. Modiano

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We previously identified two distinct molecular subtypes of osteosarcoma through gene expression profiling. These subtypes are associated with distinct tumor behavior and clinical outcomes. Here, we describe mechanisms that give rise to these molecular subtypes. Using bioinformatic analyses, we identified a significant association between deregulation of the retinoblastoma (RB)-E2F pathway and the molecular subtype with worse clinical outcomes. Xenotransplantation models recapitulated the corresponding behavior for each osteosarcoma subtype; thus, we used cell lines to validate the role of the RB-E2F pathway in regulating the prognostic gene signature. Ectopic RB resets the patterns of E2F regulated gene expression in cells derived from tumors with worse clinical outcomes (molecular phenotype 2) to those comparable with those observed in cells derived from tumors with less aggressive outcomes (molecular phenotype 1), providing a functional association between RB-E2F dysfunction and altered gene expression in osteosarcoma. DNA methyltransferase and histone deacetylase inhibitors similarly reset the transcriptional state of the molecular phenotype 2 cells from a state associated with RB deficiency to one seen with RB sufficiency. Our data indicate that deregulation of RB-E2F pathway alters the epigenetic landscape and biological behavior of osteosarcoma.

Original languageEnglish (US)
Pages (from-to)28070-28083
Number of pages14
JournalJournal of Biological Chemistry
Volume290
Issue number47
DOIs
StatePublished - Nov 20 2015

Fingerprint

Retinoblastoma
Osteosarcoma
Gene expression
Tumors
Deregulation
Phenotype
Histone Deacetylase Inhibitors
Bioinformatics
Genes
Cells
Gene Expression
DNA
Neoplasms
Heterologous Transplantation
Methyltransferases
Gene Expression Profiling
Computational Biology
Epigenomics
Cell Line

Cite this

Aberrant retinoblastoma (RB)-E2F transcriptional regulation defines molecular phenotypes of osteosarcoma. / Scott, Milcah C.; Sarver, Aaron L.; Tomiyasu, Hirotaka; Cornax, Ingrid; Van Etten, Jamie; Varshney, Jyotika; O'Sullivan, M. Gerard; Subramanian, Subbaya; Modiano, Jaime F.

In: Journal of Biological Chemistry, Vol. 290, No. 47, 20.11.2015, p. 28070-28083.

Research output: Contribution to journalArticle

Scott, Milcah C. ; Sarver, Aaron L. ; Tomiyasu, Hirotaka ; Cornax, Ingrid ; Van Etten, Jamie ; Varshney, Jyotika ; O'Sullivan, M. Gerard ; Subramanian, Subbaya ; Modiano, Jaime F. / Aberrant retinoblastoma (RB)-E2F transcriptional regulation defines molecular phenotypes of osteosarcoma. In: Journal of Biological Chemistry. 2015 ; Vol. 290, No. 47. pp. 28070-28083.
@article{fe89d804305a4054bb71961ba5c08e78,
title = "Aberrant retinoblastoma (RB)-E2F transcriptional regulation defines molecular phenotypes of osteosarcoma",
abstract = "We previously identified two distinct molecular subtypes of osteosarcoma through gene expression profiling. These subtypes are associated with distinct tumor behavior and clinical outcomes. Here, we describe mechanisms that give rise to these molecular subtypes. Using bioinformatic analyses, we identified a significant association between deregulation of the retinoblastoma (RB)-E2F pathway and the molecular subtype with worse clinical outcomes. Xenotransplantation models recapitulated the corresponding behavior for each osteosarcoma subtype; thus, we used cell lines to validate the role of the RB-E2F pathway in regulating the prognostic gene signature. Ectopic RB resets the patterns of E2F regulated gene expression in cells derived from tumors with worse clinical outcomes (molecular phenotype 2) to those comparable with those observed in cells derived from tumors with less aggressive outcomes (molecular phenotype 1), providing a functional association between RB-E2F dysfunction and altered gene expression in osteosarcoma. DNA methyltransferase and histone deacetylase inhibitors similarly reset the transcriptional state of the molecular phenotype 2 cells from a state associated with RB deficiency to one seen with RB sufficiency. Our data indicate that deregulation of RB-E2F pathway alters the epigenetic landscape and biological behavior of osteosarcoma.",
author = "Scott, {Milcah C.} and Sarver, {Aaron L.} and Hirotaka Tomiyasu and Ingrid Cornax and {Van Etten}, Jamie and Jyotika Varshney and O'Sullivan, {M. Gerard} and Subbaya Subramanian and Modiano, {Jaime F.}",
year = "2015",
month = "11",
day = "20",
doi = "10.1074/jbc.M115.679696",
language = "English (US)",
volume = "290",
pages = "28070--28083",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "47",

}

TY - JOUR

T1 - Aberrant retinoblastoma (RB)-E2F transcriptional regulation defines molecular phenotypes of osteosarcoma

AU - Scott, Milcah C.

AU - Sarver, Aaron L.

AU - Tomiyasu, Hirotaka

AU - Cornax, Ingrid

AU - Van Etten, Jamie

AU - Varshney, Jyotika

AU - O'Sullivan, M. Gerard

AU - Subramanian, Subbaya

AU - Modiano, Jaime F.

PY - 2015/11/20

Y1 - 2015/11/20

N2 - We previously identified two distinct molecular subtypes of osteosarcoma through gene expression profiling. These subtypes are associated with distinct tumor behavior and clinical outcomes. Here, we describe mechanisms that give rise to these molecular subtypes. Using bioinformatic analyses, we identified a significant association between deregulation of the retinoblastoma (RB)-E2F pathway and the molecular subtype with worse clinical outcomes. Xenotransplantation models recapitulated the corresponding behavior for each osteosarcoma subtype; thus, we used cell lines to validate the role of the RB-E2F pathway in regulating the prognostic gene signature. Ectopic RB resets the patterns of E2F regulated gene expression in cells derived from tumors with worse clinical outcomes (molecular phenotype 2) to those comparable with those observed in cells derived from tumors with less aggressive outcomes (molecular phenotype 1), providing a functional association between RB-E2F dysfunction and altered gene expression in osteosarcoma. DNA methyltransferase and histone deacetylase inhibitors similarly reset the transcriptional state of the molecular phenotype 2 cells from a state associated with RB deficiency to one seen with RB sufficiency. Our data indicate that deregulation of RB-E2F pathway alters the epigenetic landscape and biological behavior of osteosarcoma.

AB - We previously identified two distinct molecular subtypes of osteosarcoma through gene expression profiling. These subtypes are associated with distinct tumor behavior and clinical outcomes. Here, we describe mechanisms that give rise to these molecular subtypes. Using bioinformatic analyses, we identified a significant association between deregulation of the retinoblastoma (RB)-E2F pathway and the molecular subtype with worse clinical outcomes. Xenotransplantation models recapitulated the corresponding behavior for each osteosarcoma subtype; thus, we used cell lines to validate the role of the RB-E2F pathway in regulating the prognostic gene signature. Ectopic RB resets the patterns of E2F regulated gene expression in cells derived from tumors with worse clinical outcomes (molecular phenotype 2) to those comparable with those observed in cells derived from tumors with less aggressive outcomes (molecular phenotype 1), providing a functional association between RB-E2F dysfunction and altered gene expression in osteosarcoma. DNA methyltransferase and histone deacetylase inhibitors similarly reset the transcriptional state of the molecular phenotype 2 cells from a state associated with RB deficiency to one seen with RB sufficiency. Our data indicate that deregulation of RB-E2F pathway alters the epigenetic landscape and biological behavior of osteosarcoma.

UR - http://www.scopus.com/inward/record.url?scp=84947809388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947809388&partnerID=8YFLogxK

U2 - 10.1074/jbc.M115.679696

DO - 10.1074/jbc.M115.679696

M3 - Article

C2 - 26378234

AN - SCOPUS:84947809388

VL - 290

SP - 28070

EP - 28083

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 47

ER -